Anavex Life Sciences Corporation
Sector: Manufacturing
Industry: Pharmaceutical Products
8.56
0.08
(0.94%)
Volume:
834,674
52 week range:
3.51 - 14.44
Market Cap:
728.150M
Company Description:
Anavex Life Sciences Corp. engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the. treatment of Alzheimer's disease. The company's drug candidate also comprises ANaVEX 3-71 which is. in Phase I clinical. trial for frontotemporal dementia and other dementia indications.